89BIO (ETNB)
(Delayed Data from NSDQ)
$8.63 USD
-0.34 (-3.79%)
Updated May 17, 2024 04:00 PM ET
After-Market: $8.62 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ETNB 8.63 -0.34(-3.79%)
Will ETNB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ETNB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ETNB
All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy
Novo Nordisk (NVO) Down Despite Kidney Outcomes Study Success
ETNB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade
89BIO (ETNB) Just Overtook the 200-Day Moving Average
Other News for ETNB
RBC Capital Remains a Hold on 89bio (ETNB)
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Celcuity (CELC) and 89bio (ETNB)
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Ionis Pharmaceuticals (IONS) and 89bio (ETNB)
Wall Street Analysts Are Bullish on Top Healthcare Picks
Buy Rating for 89bio on Pegozafermin’s Promise in Advanced NASH Trials